BLAB — Britannia Life Sciences Balance Sheet
0.000.00%
- CA$9.74m
- CA$20.51m
- CA$7.57m
- 29
- 34
- 35
- 23
Annual balance sheet for Britannia Life Sciences, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2019 November 30th | 2020 November 30th | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.254 | 0.069 | 1.63 | 2.6 | 1.32 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.074 | 0.099 | 1.79 | 1.6 | 1.21 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2.46 | 0.18 | 3.48 | 4.22 | 2.73 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.116 | 0.078 | 0.546 | 0.452 | 0.721 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 3.16 | 0.257 | 21.1 | 23.5 | 22.3 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11.7 | 13.4 | 8.32 | 4.6 | 10.5 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 13.2 | 13.5 | 19.7 | 16.5 | 19.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -10.1 | -13.2 | 1.35 | 7.02 | 2.44 |
Total Liabilities & Shareholders' Equity | 3.16 | 0.257 | 21.1 | 23.5 | 22.3 |
Total Common Shares Outstanding |